FBIO
Fortress Biotech, Inc.
Biotechnology
Market Cap$67M
5Y Perf.-94.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FBIO vs MNOV
Revenue, margins, valuation, and 5-year total return — side by side.
MNOV
MediciNova, Inc.
Biotechnology
Market Cap$70M
5Y Perf.-73.2%
FBIO vs MNOV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FBIO | MNOV |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $67M | $70M |
| Revenue (TTM) | $62M | $410K |
| Net Income (TTM) | $4M | $-12M |
| Gross Margin | 65.8% | 7.6% |
| Operating Margin | -149.2% | -32.4% |
| Forward P/E | 240.0x | — |
| Total Debt | $76M | $194K |
| Cash & Equiv. | $57M | $31M |
FBIO vs MNOV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FBIO
MNOV
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | 100 | 5.5 | -94.5% |
| MediciNova, Inc. (MNOV) | 100 | 26.8 | -73.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FBIO vs MNOV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FBIO leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. MediciNova, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
FBIO
Fortress Biotech, Inc.
The Growth Play
FBIO carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth -31.8%, EPS growth 68.2%, 3Y rev CAGR -5.7%
- 6.4% margin vs MNOV's -29.3%
- 1.4% yield; the other pay no meaningful dividend
Best for: growth exposure
MNOV
MediciNova, Inc.
The Income Pick
MNOV is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.31
- -80.1% 10Y total return vs FBIO's -94.8%
- Lower volatility, beta 0.31, Low D/E 0.5%, current ratio 8.16x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNOV | -8.8% revenue growth vs FBIO's -31.8% |
| Quality / Margins | FBIO | 6.4% margin vs MNOV's -29.3% |
| Stability / Safety | MNOV | Beta 0.31 vs FBIO's 0.97 |
| Dividends | FBIO | 1.4% yield; the other pay no meaningful dividend |
| Momentum (1Y) | FBIO | +39.5% vs MNOV's -4.0% |
| Efficiency (ROA) | FBIO | 2.2% ROA vs MNOV's -26.3%, ROIC -6.3% vs -85.5% |
FBIO vs MNOV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
FBIO vs MNOV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNOVLAGGINGFBIO
FBIOFortress Biotech, Inc.
1leads
MNOVMediciNova, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs FBIOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FBIO5/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNOV5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
MNOV5/6
Risk & VolatilityBeta, volatility, and downside exposure
MNOV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FBIO leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
FBIO is the larger business by revenue, generating $62M annually — 152.1x MNOV's $409,657. FBIO is the more profitable business, keeping 6.4% of every revenue dollar as net income compared to MNOV's -29.3%.
| Metric | FBIOFortress Biotech,… | MNOVMediciNova, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $62M | $409,657 |
| EBITDAEarnings before interest/tax | -$88M | -$13M |
| Net IncomeAfter-tax profit | $4M | -$12M |
| Free Cash FlowCash after capex | -$66M | -$10M |
| Gross MarginGross profit ÷ Revenue | +65.8% | +7.6% |
| Operating MarginEBIT ÷ Revenue | -149.2% | -32.4% |
| Net MarginNet income ÷ Revenue | +6.4% | -29.3% |
| FCF MarginFCF ÷ Revenue | -106.2% | -23.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +20.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +114.5% | +4.7% |
FBIO leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
Evenly matched — FBIO and MNOV each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | FBIOFortress Biotech,… | MNOVMediciNova, Inc. |
|---|---|---|
| Market CapShares × price | $67M | $70M |
| Enterprise ValueMkt cap + debt − cash | $86M | $40M |
| Trailing P/EPrice ÷ TTM EPS | -0.89x | -5.96x |
| Forward P/EPrice ÷ next-FY EPS est. | 240.00x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.16x | 171.21x |
| Price / BookPrice ÷ Book value/share | — | 1.69x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — FBIO and MNOV each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNOV leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
FBIO delivers a 6.1% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-29 for MNOV. On the Piotroski fundamental quality scale (0–9), MNOV scores 3/9 vs FBIO's 1/9, reflecting mixed financial health.
| Metric | FBIOFortress Biotech,… | MNOVMediciNova, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +6.1% | -28.9% |
| ROA (TTM)Return on assets | +2.2% | -26.3% |
| ROICReturn on invested capital | -6.3% | -85.5% |
| ROCEReturn on capital employed | -142.0% | -28.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | $19M | -$31M |
| Cash & Equiv.Liquid assets | $57M | $31M |
| Total DebtShort + long-term debt | $76M | $194,331 |
| Interest CoverageEBIT ÷ Interest expense | -4.25x | — |
MNOV leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
MNOV leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNOV five years ago would be worth $3,488 today (with dividends reinvested), compared to $406 for FBIO. Over the past 12 months, FBIO leads with a +39.5% total return vs MNOV's -4.0%. The 3-year compound annual growth rate (CAGR) favors MNOV at -13.2% vs FBIO's -40.0% — a key indicator of consistent wealth creation.
| Metric | FBIOFortress Biotech,… | MNOVMediciNova, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -40.4% | +7.5% |
| 1-Year ReturnPast 12 months | +39.5% | -4.0% |
| 3-Year ReturnCumulative with dividends | -78.4% | -34.7% |
| 5-Year ReturnCumulative with dividends | -95.9% | -65.1% |
| 10-Year ReturnCumulative with dividends | -94.8% | -80.1% |
| CAGR (3Y)Annualised 3-year return | -40.0% | -13.2% |
MNOV leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
MNOV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MNOV is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than FBIO's 0.97 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNOV currently trades 73.0% from its 52-week high vs FBIO's 53.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FBIOFortress Biotech,… | MNOVMediciNova, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.97x | 0.31x |
| 52-Week HighHighest price in past year | $4.53 | $1.96 |
| 52-Week LowLowest price in past year | $1.60 | $1.17 |
| % of 52W HighCurrent price vs 52-week peak | +53.0% | +73.0% |
| RSI (14)Momentum oscillator 0–100 | 54.7 | 55.8 |
| Avg Volume (50D)Average daily shares traded | 407K | 47K |
MNOV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
FBIO is the only dividend payer here at 1.39% yield — a key consideration for income-focused portfolios.
| Metric | FBIOFortress Biotech,… | MNOVMediciNova, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | 6 | — |
| Dividend YieldAnnual dividend ÷ price | +1.4% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.03 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNOV leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). FBIO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallMediciNova, Inc. (MNOV)Leads 3 of 6 categories
Loading custom metrics...
FBIO vs MNOV: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is FBIO or MNOV a better buy right now?
Analysts rate Fortress Biotech, Inc.
(FBIO) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FBIO or MNOV?
Over the past 5 years, MediciNova, Inc.
(MNOV) delivered a total return of -65. 1%, compared to -95. 9% for Fortress Biotech, Inc. (FBIO). Over 10 years, the gap is even starker: MNOV returned -80. 1% versus FBIO's -94. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FBIO or MNOV?
By beta (market sensitivity over 5 years), MediciNova, Inc.
(MNOV) is the lower-risk stock at 0. 31β versus Fortress Biotech, Inc. 's 0. 97β — meaning FBIO is approximately 215% more volatile than MNOV relative to the S&P 500.
04Which is growing faster — FBIO or MNOV?
On earnings-per-share growth, the picture is similar: Fortress Biotech, Inc.
grew EPS 68. 2% year-over-year, compared to -4. 3% for MediciNova, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — FBIO or MNOV?
Fortress Biotech, Inc.
(FBIO) is the more profitable company, earning -79. 8% net margin versus -29. 3% for MediciNova, Inc. — meaning it keeps -79. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FBIO leads at -191. 4% versus -32. 4% for MNOV. At the gross margin level — before operating expenses — FBIO leads at 63. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — FBIO or MNOV?
In this comparison, FBIO (1.
4% yield) pays a dividend. MNOV does not pay a meaningful dividend and should not be held primarily for income.
07Is FBIO or MNOV better for a retirement portfolio?
For long-horizon retirement investors, MediciNova, Inc.
(MNOV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 31)). Both have compounded well over 10 years (MNOV: -80. 1%, FBIO: -94. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between FBIO and MNOV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
FBIO pays a dividend while MNOV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.